夹脊穴结合局部围针治疗带状疱疹后遗神经痛的Meta分析

背景：临床应用夹脊穴结合局部围针治疗带状疱疹后遗神经痛取得了良好的疗效,但其效果是否优于西药尚不明确。 目的：系统评价夹脊穴结合局部围针治疗带状疱疹后遗神经痛的有效性。 方法：计算机检索中国知网数据库、维普全文期刊数据库、中国生物医学文献数据库、Pubmed医学文献检索服务系统、美国斯坦福大学的Highwire数据库,手工检索南京中医药大学图书馆过刊资料库及相关会议论文集,检索时间为建库至2010-07,收集夹脊穴结合局部围针治疗带状疱疹后遗神经痛的临床随机对照试验,并按照循证医学原则对文献质量进行评价。统计学分析采用RevMan 4.2软件。采用总有效率、临床治愈率、疼痛目测类比评分、临床症状评分等作为结局评价指标。 结果与结论：共纳入13个随机对照试验(共858例)。Meta分析结果显示,夹脊穴结合局部围针治疗带状疱疹后遗神经痛在总有效率[RR=1.26,95%CI(1.19,1.34)]、临床治愈率[RR=1.93,95%CI(1.64,2.27)]、疼痛目测类比评分[WMD=3.13,95%CI(2.38,3.87)]方面明显优于对照组。总有效率分类比较显示,夹脊穴结合围针的效果与物理治疗差异无显著性意义[RR=1.60,95%CI(0.43,6.02)],但明显优于卡马西平[RR=1.45,95%CI(1.22,1.72)]。说明夹脊穴结合局部围针治疗带状疱疹后遗神经痛的疗效优于西药,但尚需要更多高质量的随机双盲对照试验来进一步证实其疗效。     

针刺联合抗抑郁药治疗抑郁症44例临床观察

目的 观察针刺介入治疗抑郁症的临床疗效及不良反应.方法 将98例抑郁症患者随机分为药物对照组54例、针刺介入组44例,两组患者均酌情选用1种选择性5-羟色胺再摄取抑制剂(SSRI)类抗抑郁药口服,连续治疗6周;针刺介入组在此基础上针刺神庭、百会、风池、大椎、神道、至阳并随症加减治疗.记录两组在治疗前和治疗第1、2、4、6周及随访时汉密尔顿抑郁量表(H AMD)总评分,以及治疗第1、2、4、6周时副反应量表(SERS)评分,并根据HAMD减分率统计疗效. 结果 药物对照组愈显率为61.11％、总有效率为85.19％,针刺介入组分别为90.90％、100％,两组愈显率比较差异有统计学意义(P＜0.01),总有效率比较差异有统计学意义(P＜0.05).针刺介入组HAMD总分在治疗第1、2、4、6周时均明显低于药物对照组(P＜0.05或P＜0.01);针刺介入组SERS评分在治疗第2、4、6周时均明显低于药物对照组(P＜0.01).结论 针刺介入治疗抑郁症临床疗效优于单用药物治疗,主要表现为起效快且能明显减轻药物不良反应等.     

How Much and How Long: Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia

As the first clinically successful tyrosine kinase inhibitor (TKI), imatinib pioneered a new approach to treating patients with cancer. Dramatic results from chronic myeloid leukemia (CML) clinical trials spurred the development of TKIs for other malignancies such as acute myeloid leukemia as well as kidney and lung cancer. In CML, imatinib resistance led to the rapid development of dasatinib and nilotinib, more potent second-generation ABL kinase inhibitors that can often overcome imatinib resistance. While the clinical efficacy of TKIs in CML is well established, a number of important questions remain about the optimal dose and duration of therapy. Even the best initial dose for imatinib is still under investigation. Although laboratory and clinical studies had led to the prevailing view that continual inhibition of the BCR-ABL kinase was required for optimal efficacy, recent data on dasatinib have upended this notion and have led to a change in the recommended dosing schedule. The availability of dasatinib and nilotinib also begs the question of whether they might be superior to imatinib as first-line agents. Finally, the question of whether it may be possible to stop TKI therapy at least in some patients with CML has attracted considerable attention. More than 10 years after the introduction of imatinib, optimization of TKI therapy for CML continues.     

骨形态发生蛋白与碱性成纤维细胞生长因子联合修复软骨缺损的效果评价*

背景：多种细胞生长因子在骨软骨代谢过程中的协同作用越来越受到重视,但目前复合细胞生长因子修复软骨缺损报道较少,且修复效果尚无定论。 目的：探讨骨形态发生蛋白和碱性成纤维细胞生长因子联合应用修复关节软骨缺损的效果。 方法：24只日本大耳白兔建立骨软骨缺损模型后随机等分为4组,对照组缺损处仅填塞明胶海绵,其他3组在对照组基础上,缺损处分别注射骨形态发生蛋白和碱性成纤维细胞生长因子、骨形态发生蛋白、碱性成纤维细胞生长因子。 结果与结论：大体观察显示联合应用2种细胞因子后,软骨缺损面基本修复但稍不平整,单独使用其中1种细胞因子缺损面未完全修复,对照组无明显修复。联合应用2种细胞因子缺损部位软骨细胞数多于其他3组(P < 0.05),且Ⅱ型胶原免疫组化染色深于其他组。提示联合应用骨形态发生蛋白和碱性成纤维细胞生长因子可以促进关节软骨损伤的修复,疗效优于单独应用骨形态发生蛋白或碱性成纤维细胞生长因子。 关键词：骨形态发生蛋白;碱性成纤维细胞生长因子;修复;软骨缺损;细胞因子 doi:10.3969/j.issn.1673-8225.2012.11.003     

胫骨远端骨折有限元模型的建立及稳定性分析

BACKGROUND: Traditional studies on foot and ankle biomechanics have limitation. Ankle joint was complicated and had big range of motion, so it is difficult to establish finite element models and to analyze the type of fracture.     

Peperomia pellucida (L.) Kunth and eye diseases: A review on phytochemistry,pharmacology and toxicology

Peperomia pellucida (L.) Kunth is a medicinal plant used to manage inflammatory illnesses such as conjunctivitis, and gastrointestinal and respiratory tract disorders in tropical and subtropical regions. However, little is known about its pharmacological mechanism of action against eye diseases. This review aims to critically discuss the phytochemistry, pharmacology and toxicology of P. pellucida as well as its roles in the treatment of cataract, glaucoma and diabetic retinopathy. Recent developments in the uses of P. pellucida for healthcare and nutraceutical products by the pharmaceutical industry are also covered in this review. For this review, a literature search was performed with PubMed, ScienceDirect, SciFinder Scholar and Scopus databases, using relevant keywords. Among the various phytochemicals identified from P. pellucida, β-caryophyllene, carotol, dillapiole, ellagic acid, pellucidin A, phytol and vitexin exhibit strong pharmacological activities within the mitogen-activated protein kinase and nuclear factor-κB signalling pathways in inflammatory eye diseases. The antihypertensive, anti-inflammatory, antioxidant, antihyperglycemic and anti-angiogenic activities displayed by P. pellucida extracts in many in vitro, in vivo and clinical studies suggest its potential role in the management of inflammatory eye diseases. P. pellucida extract was non-toxic against normal cell lines but displayed mild toxicity in animal models. The growing public interest in P. pellucida has inspired the nutraceutical and pharmaceutical industries to process the plant into health products. Although the potential pharmacological mechanisms against eye diseases have been summarized, further studies of the interactions among constituent phytochemicals from P. pellucida within various signalling pathways shall support the use of the plant as an alternative therapeutic source.     

Safety,Efficacy, and Pharmacokinetics of Rezivertinib (BPI-7711) in Patients With Advanced NSCLC With EGFR T790M Mutation: A Phase 1 Dose-Escalation and Dose-Expansion Study

IntroductionRezivertinib (BPI-7711) is a novel third-generation EGFR tyrosine kinase inhibitor selective for EGFR-sensitizing and T790M mutations. This study was designed to evaluate the safety, efficacy, and pharmacokinetics of rezivertinib for patients having advanced NSCLC with EGFR T790M mutation.MethodsThis phase 1 study (NCT03386955) was conducted across 20 sites in the People's Republic of China. Patients received rezivertinib at six oral dose levels (30 mg, 60 mg, 120 mg, 180 mg, 240 mg, 300 mg) once daily until disease progression, unacceptable toxicity, or patient withdrawal. The primary end points were safety for the dose-escalation phase and objective response rate by the blinded independent central review for the total study population.ResultsA total of 19 patients in dose-escalation phase using the standard 3 + 3 design principle and 153 patients in dose-expansion phase were enrolled from September 11, 2017, to August 23, 2019. The data cutoff date was on June 15, 2020. No dose-limiting toxicity occurred in the dose-escalation phase. The treatment-related adverse events were observed in 82.0% (141 of 172) of patients, and 17.4% (30 of 172) had grade greater than or equal to 3, among which decreased neutrophil count (2.9%), leukopenia (2.9%), and pneumonia (2.9%) were the most common. The overall blinded independent central review–evaluated objective response rate was 59.3% (102 of 172, 95% confidence interval: 51.6–66.7), and the median progression-free survival was 9.7 (95% confidence interval: 8.3–11.1) months.ConclusionsRezivertinib was found to have promising efficacy with a manageable safety profile in patients with EGFR T790M-mutated advanced NSCLC. Further study is warranted.     

节拍化疗模式下卡培他滨强化依西美坦抑制乳腺癌MCF-7细胞增殖的实验研究

目的:研究节拍化疗模式下卡培他滨联合依西美坦对乳腺癌MCF-7细胞的增殖抑制作用及信号通路机制。方法:实验分为7组,CCK-8法检测单药与联合用药组对MCF-7细胞增殖的抑制率。流式细胞仪检测分析药物作用对MCF-7细胞周期与细胞凋亡的影响。Western blot法检测各用药组MCF-7细胞p27、Bcl-2、PI3K和AKT蛋白的表达情况。结果:卡培他滨的半数抑制浓度（half maximal inhibitory concentration,IC50)为282.7 μmol/L、依西美坦IC50为103.5 μmol/L;联合用药组对MCF-7细胞增殖的抑制率高于单药组（P=0.003）;联合用药组中减小卡培他滨剂量不会显著降低细胞增殖抑制率（P=0.916）;与单药组影响细胞周期不同,联合用药会使MCF-7细胞停滞于S期或G1期;Western blot检测显示,联合用药会促进p27表达,抑制PI3K表达,促使细胞凋亡;低剂量卡培他滨会显著抑制Bcl-2表达（P=0.006）,使细胞停滞于S期。结论:小剂量卡培他滨节拍化疗联合依西美坦通过不同模式多方位影响MCF-7细胞周期及信号因子表达,显著抑制MCF-7细胞增殖。